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rates, encouraging survival rates and very low grade III-IV
aGvHD and extensive cGVHD rates despite relatively high T
cells doses. The results from this relatively small number of
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Methods: A prospective studywas conducted to characterize
the pharmacokinetics (PK) of ﬂudarabine plasma (f-ara-A)
and intracellular triphosphate (f-ara-ATP) in children
undergoing alloHCT and receiving ﬂudarabine with their
conditioning regimen. Plasma and peripheral blood mono-
nuclear cells (PBMCs) were collected over the 3-5 days of
ﬂudarabine treatment for quantitation of f-ara-A and f-ara-
ATP, respectively, using a validated liquid chromatography/
tandem mass spectrometry assay. Nonlinear mixed effects
modeling was used to develop the population PK model,
including identiﬁcation of covariates that inﬂuenced drug
disposition.
Results: Fifty-four children (median age 2 years, range 0.25-
17) undergoing alloHCT for a variety of malignant and
nonmalignant disorders underwent PK assessments. A 2-
compartment model with linear elimination best described
the PK of f-ara-A while a third compartment representing
PBMCs linked f-ara-A to f-ara-ATP. Final parameter estimates
and relative standard errors for f-ara-A are as follows:
clearance, 5.8 L/h (5.4%), volume of central compartment,
16.6 L (9.0%), volume of peripheral compartment, 16.6 L
(5.8%), and intercompartmental clearance, 3.0 L/h (14.1%).
Covariates signiﬁcantly impacting f-ara-A clearance included
body weight, age, and creatinine clearance (CrCL). Dose-
normalized PK exposure was highest among very small,
young children or subjects with renal dysfunction. Predicted
f-ara-A clearancewas reduced 40% in subjects with CrCL 50
mL/min compared to those with normal renal function (120
mL/min). Additionally, the rate of f-ara-A into PBMCs and/or
transformation to f-ara-ATP (modeled with a ﬁrst order rate
constant) decreased over the course of therapy, resulting in
42% lower intracellular f-ara-ATP exposure following the
third versus ﬁrst dose.
Impact: These results will help inform better dosing strate-
gies for ﬂudarabine, particularly in young infants with small
body size or in children with pre-existing renal dysfunction.
Re-evaluation of the optimal dosing regimen for ﬂudarabine
is warranted given the decrease in intracellular exposure to f-
ara-ATP with time.12
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AlloPBHCT compared to bone marrow transplants have a
decreased time to engraftment due to higher levels of CD34+
cells in the graft. However, the correlation of CD34+, CD3+,
CD4+, CD8+ and total nucleated cell (TNC) dose with out-
comes after alloPBHCT have been inconsistent. We retro-
spectively analyzed graft cell composition, focusing on
conditioning regimen intensity +/- total body irradiation
(TBI), in 254 consecutive ﬁrst alloPBHCT patients from 1/
2001 to 9/2012. Patient characteristics are: 58% male, 76%
40 years, 56% related/44% unrelated donor, 44% AML, 18%
MDS/MPD, 13% ALL, 13% NHL, 12% other diseases, 49% in CR
pre-PBHCT. 94 patients hadmyeloablative (MA) conditioning
with (n¼53) or without (n¼41) TBI. 160 patients had reduced
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TBI. CD3+, CD4+ and CD8+ doses were analyzed above vs.
below the median dose. TNC dose was analyzed < vs  8 x
108 cells/kg; CD34+ was analyzed< vs 4 x 106 cells/kg. The
median (range) follow-up was 3.2 (<0.1-11) years. Time to
neutrophil engraftment was shorter in patients with  4 x
106 CD34+ cells/kg (14 vs 15 days, P¼.051), but was only
signiﬁcant in TBI-based conditioning (P¼.007 TBI, P¼NS no
TBI). Time to platelet engraftment was also signiﬁcantly
shorter in patients with  4 x 106 CD34+ cells/kg (17 vs 21
days, P¼.004); but was only signiﬁcant in the MA+TBI
(P¼.001) and RIC-noTBI (P¼.023) subgroups. CD34+ dose was
not associated with overall survival (OS) (Figure, Table),
progression free survival (PFS, Table) or development of
acute GVHD (grade II-IV or III-IV), either in the entire cohort
or in any conditioning subgroups. CD3+, CD4+ and CD8+ cell
doses were not associated with any outcomes in the entire
cohort or in any conditioning subgroups. OS and PFS were
both improved for patients receiving either a MA or RICTBI-based regimen and a TNC 8 x 108 cells/kg (Figure,
Table). The TNC dose did not correlate with CD34+ dose and
is therefore an independent predictor of outcomes. Our study
suggests that understanding blood graft cell composition is
needed, and that conditioning regimen may inﬂuence the
desired cell dose. Further study may allow us to identify
which cell population in the TNC is associated with out-
comes.13
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Purpose: The effect of sequencing Cy and myeloablative
doses of TBI in the conditioning regimen on HCT outcomes in
humans is unknown. In rodent experiments, however, it has
been suggested that TBI followed by Cy (TBICy) is superior in
reducing lung toxicity, but also results in an increased inci-
dence of bone marrow damage. In contrast, Cy followed by
TBI (CyTBI) has been reported to be associated with an
improved anti-leukemic effect with increased risk of hepatic
sinusoidal obstructive syndrome (SOS).
Study Design: The sequence of Cy and TBI (1200-1500cGY)
was evaluated in 1,769 recipients of related or unrelated
donor HCT, younger than 60 years with acute leukemia (AML
n¼945, ALL¼ 824) who were reported to the Center for In-
ternational Blood andMarrow Transplant Research (CIBMTR)
from 2003 to 2010.Patient Characteristics Cy TBI TBI Cy
Median Age 35 34
Performance status> 90 69% 74%
AML 52% 55%
CR1 64% 64%
Ph+ ALL 25% 25%
BM stem cell source 34% 37%
HLA sibling 35% 34%
ATG 11% 13%
TBI dose 1200-1300 cGy 61% 63%
Tacrolimus/Methotrexate 43% 45%
